Health · 9 views
'Pan-RAS molecular glue' is a safe and effective treatment for lung and pancreatic cancers
Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.
AI Summary
The Phase I AURORAS‑1 trial of ERAS‑0015, an anticancer drug, showed the treatment is safe and produced tumor shrinkage in patients with hard‑to‑treat lung and pancreatic cancers. The study enrolled 148 patients and was presented at the 38th EORTC‑NCI‑AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. ERAS‑0015 specifically targets tumors driven by mutations in the RAS gene, a target previously considered difficult to drug. The results suggest that designing drugs against RAS mutations is now feasible.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Major data gap for gut disorders leaves Aotearoa in the darkContinue reading
- Federal court indefinitely pauses military's plans for detonation of unstable explosives in IowaContinue reading
- Mental health diagnoses rise with medical complexity, chronicity in childrenContinue reading
- Flu vaccine effectiveness often weaker than advertised, study findsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow